FDAnews
www.fdanews.com/articles/180933-effector-wins-orphan-designation-from-fda-in-diffuse-large-b-cell-lymphoma

Effector Wins Orphan Designation from FDA in Diffuse Large B-Cell Lymphoma

March 16, 2017

Effector Therapeutics has gained orphan drug designation from the FDA for its drug candidate, eft508, for the treatment of diffuse large B-cell lymphoma.

The drug candidate is a highly selective and orally bioavailable inhibitor of MNK1 and MNK2, two enzymes that are critical for the growth and survival of tumors, are being studied in patients with solid tumors and lymphoma.

The primary goals will be to establish a maximum tolerated dose and recommended dose for further evaluation and to assess preliminary efficacy of the compound.

View today's stories